186 related articles for article (PubMed ID: 33742034)
21. Leukapheresis do not improve early death rates in acute myeloid leukemia patients with hyperleukocytosis.
Malkan UY; Ozcebe OI
Transfus Apher Sci; 2017 Dec; 56(6):880-882. PubMed ID: 29153308
[TBL] [Abstract][Full Text] [Related]
22. Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study.
Stahl M; Shallis RM; Wei W; Montesinos P; Lengline E; Neukirchen J; Bhatt VR; Sekeres MA; Fathi AT; Konig H; Luger S; Khan I; Roboz GJ; Cluzeau T; Martínez-Cuadron D; Raffoux E; Germing U; Umakanthan JM; Mukherjee S; Brunner AM; Miller A; McMahon CM; Ritchie EK; Rodríguez-Veiga R; Itzykson R; Boluda B; Rabian F; Tormo M; Acuña-Cruz E; Rabinovich E; Yoo B; Cano I; Podoltsev NA; Bewersdorf JP; Gore S; Zeidan AM
Leukemia; 2020 Dec; 34(12):3149-3160. PubMed ID: 32132655
[TBL] [Abstract][Full Text] [Related]
23. Clinical characteristics and outcomes of children with newly diagnosed acute myeloid leukemia and hyperleukocytosis managed with different cytoreductive methods.
Christakopoulos GE; Walker KN; Smith J; Takemoto CM; Zheng Y; Pui CH; Ribeiro RC; Wang L; Pounds SB; Rubnitz JE; Inaba H
Cancer; 2023 Jun; 129(12):1873-1884. PubMed ID: 36943896
[TBL] [Abstract][Full Text] [Related]
24. Initial respiratory status in hyperleukocytic acute myeloid leukemia: prognostic significance and effect of leukapheresis.
Van de Louw A; Schneider CW; Desai RJ; Claxton DF
Leuk Lymphoma; 2016; 57(6):1319-26. PubMed ID: 26374497
[TBL] [Abstract][Full Text] [Related]
25. Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant.
Ahn JS; Kim JY; Kim HJ; Kim YK; Lee SS; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Minden MD; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
Ann Hematol; 2016 Jan; 95(2):301-10. PubMed ID: 26537612
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of CEBPA mutations and BAALC expression in acute myeloid leukemia Egyptian patients with normal karyotype.
El-Sharnouby JA; Ahmed LM; Taha AM; Kamal O
Egypt J Immunol; 2008; 15(1):131-43. PubMed ID: 20306678
[TBL] [Abstract][Full Text] [Related]
27. Multilineage dysplasia does not influence prognosis in CEBPA-mutated AML, supporting the WHO proposal to classify these patients as a unique entity.
Bacher U; Schnittger S; Macijewski K; Grossmann V; Kohlmann A; Alpermann T; Kowarsch A; Nadarajah N; Kern W; Haferlach C; Haferlach T
Blood; 2012 May; 119(20):4719-22. PubMed ID: 22442349
[TBL] [Abstract][Full Text] [Related]
28. Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system.
Weinberg OK; Seetharam M; Ren L; Seo K; Ma L; Merker JD; Gotlib J; Zehnder JL; Arber DA
Blood; 2009 Feb; 113(9):1906-8. PubMed ID: 19131546
[TBL] [Abstract][Full Text] [Related]
29. Leukapheresis in childhood acute leukemias: single-center experience.
Yilmaz D; Karapinar B; Karadaş N; Duyu M; Yazici P; Ay Y; Balkan C; Aydinok Y; Kavakli K
Pediatr Hematol Oncol; 2014 May; 31(4):318-26. PubMed ID: 23988130
[TBL] [Abstract][Full Text] [Related]
30. Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome.
Dufour A; Schneider F; Metzeler KH; Hoster E; Schneider S; Zellmeier E; Benthaus T; Sauerland MC; Berdel WE; Büchner T; Wörmann B; Braess J; Hiddemann W; Bohlander SK; Spiekermann K
J Clin Oncol; 2010 Feb; 28(4):570-7. PubMed ID: 20038735
[TBL] [Abstract][Full Text] [Related]
31. Leukapheresis Does Not Improve Early Survival Outcome of Acute Myeloid Leukemia with Leukostasis Patients - A Dual-Center Retrospective Cohort Study.
Rinaldi I; Sari RM; Tedhy VU; Winston K
J Blood Med; 2021; 12():623-633. PubMed ID: 34290537
[TBL] [Abstract][Full Text] [Related]
32. Favorable prognosis of biallelic CEBPA gene mutations in acute myeloid leukemia patients: a meta-analysis.
Li HY; Deng DH; Huang Y; Ye FH; Huang LL; Xiao Q; Zhang B; Ye BB; Lai YR; Mo ZN; Liu ZF
Eur J Haematol; 2015 May; 94(5):439-48. PubMed ID: 25227715
[TBL] [Abstract][Full Text] [Related]
33. [Treatment of leukemia relapsed after allogenic bone marrow transplantation with donor lymphocyte infusion: report of 11 cases].
Sanz Rodríguez C; Steegmann JL; Granda A; de la Cámara R; Figuera A; Arranz R; Gómez-García de Soria V; Alegre A; Fernández-Rañada JM
Sangre (Barc); 1999 Dec; 44(6):456-63. PubMed ID: 10822760
[TBL] [Abstract][Full Text] [Related]
34. Comparison of early mortality between leukapheresis and non-leukapheresis in adult acute myeloid leukemia patients with hyperleukocytosis: a systematic review and meta-analysis.
Rinaldi I; Sutandyo N; Winston K
Hematology; 2022 Dec; 27(1):141-149. PubMed ID: 35068391
[TBL] [Abstract][Full Text] [Related]
35. Normal karyotype acute myeloid leukemia with the CD7+ CD15+ CD34+ HLA-DR + immunophenotype is a clinically distinct entity with a favorable outcome.
Iriyama N; Asou N; Miyazaki Y; Yamaguchi S; Sato S; Sakura T; Maeda T; Handa H; Takahashi M; Ohtake S; Hatta Y; Sakamaki H; Honda S; Taki T; Taniwaki M; Miyawaki S; Ohnishi K; Kobayashi Y; Naoe T
Ann Hematol; 2014 Jun; 93(6):957-63. PubMed ID: 24441947
[TBL] [Abstract][Full Text] [Related]
36. [Clinical characteristics and therapeutic efficacy of normal karyotype AML patients with CEBPA mutation].
Du YZ; Su L; Li W; Yu P; Tan YH; Lin H; Gao SJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Feb; 22(1):16-9. PubMed ID: 24598643
[TBL] [Abstract][Full Text] [Related]
37. Effectiveness of leukapheresis on early survival in acute myeloid leukemia: An observational propensity score matching cohort study.
Lee H; Han JH; Kim JK; Yoo J; Cho HS; Yoon JH; Cho BS; Kim HJ; Lim J; Jekarl DW; Kim Y
J Clin Apher; 2023 Dec; 38(6):727-737. PubMed ID: 37786990
[TBL] [Abstract][Full Text] [Related]
38. Minimally early morbidity in children with acute myeloid leukemia and hyperleukocytosis treated with prompt chemotherapy without leukapheresis.
Chen KH; Liu HC; Liang DC; Hou JY; Huang TH; Chang CY; Yeh TC
J Formos Med Assoc; 2014 Nov; 113(11):833-8. PubMed ID: 24534017
[TBL] [Abstract][Full Text] [Related]
39. Leukapheresis for the management of hyperleukocytosis in acute myeloid leukemia-A systematic review and meta-analysis.
Bewersdorf JP; Giri S; Tallman MS; Zeidan AM; Stahl M
Transfusion; 2020 Oct; 60(10):2360-2369. PubMed ID: 32776542
[TBL] [Abstract][Full Text] [Related]
40. Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML.
Ahn JS; Kim HJ; Kim YK; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
Ann Hematol; 2016 Mar; 95(4):625-35. PubMed ID: 26692090
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
